Construction method and application of MBL point mutation animal model
The G54D point mutation model of the MBL2 gene was established in mice through CRISPR/Cas9 technology, which solved the problem that the MBL complete knockout mouse model in the existing technology is not suitable for studying autoimmune diseases, and achieved the G54D point mutation. In-depth research in IgA nephropathy and exploration of potential therapeutic targets.
Patent Information
- Application Number
- CN202311847437.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-28
- Publication Date
- 2024-11-22
AI Technical Summary
The existing MBL complete knockout mouse model is not suitable for studying specific autoimmune diseases, such as IgA nephropathy, and does not involve the immune animal model of MBL2-related point mutation mice, and it is impossible to understand the G54D point mutation in the disease. Mechanism of action in progress.
CRISPR/Cas9 technology was used to perform specific gene editing on the mouse genome, and a G54D point mutant mouse model of the MBL2 gene was established. Gene mutations were constructed by synthesizing gRNA and Donor Oligo, preparing RNP complexes, injecting fertilized eggs and passages.
A G54D point mutation mouse model of MBL2 gene was successfully established to study the mechanism of G54D point mutation in IgA nephropathy and its importance as a potential therapeutic target. It provides a tool for drug screening and drug efficacy research to help understand G54D The role of point mutations in autoimmune diseases.
Smart Images

Figure CN118995828A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of animal model construction, and particularly relates to a method for constructing an MBL point mutation animal model. Background Art
[0002] Mannose binding lectin (MBL) mutant mice play an important role in the study of host defense. The MBL mutant mice currently constructed are all completely knocked out mice. For example, in the liver (the main site of MBL synthesis) of MBL-A and MBL-C mice (MBL-null), there is no endogenous gene expression, and MBL protein cannot be detected in the serum. This type of mouse has a high survival rate, strong fertility, normal body shape, and no obvious developmental defects. Histological examinations of multiple organs of mice aged 6-10 weeks also did not find abnormalities. Complement activity detection found that although the classical complement pathway of MBL-null mice was not affected, the complement lectin-dependent pathway did not work.
[0003] At present, MBL-deficient mice are mostly used to study host defense, including inflammation and infection, apoptosis, and abnormal activation of the complement pathway in ischemia-reperfusion models. For example, after intravenous injection of Staphylococcus aureus, the mortality of MBL-deficient mice increased, and the levels of TNF-α and IL-6 in serum were abnormal (decreased 2 hours after injection and increased after 24 hours); MBL-null mice were inoculated with Staphylococcus aureus after febrile neutropenia induced by the chemotherapy drug cyclophosphamide, and their susceptibility to abscess formation in the kidneys, liver, and lungs increased significantly. Even if the circulating neutrophils returned to normal levels, these mice still had persistent bacteremia; in addition, MBL-deficient mice had increased susceptibility to infection with Pseudomonas aeruginosa after burns; after injection of herpes simplex virus-2, their liver had defective clearance of the virus; studies have found that mutant mice were protected from organ damage after bilateral renal ischemia-reperfusion and myocardial ischemia-reperfusion (I / R), accompanied by increased C3.
[0004] IgA nephropathy is one of the most common primary glomerulonephritis in the world and is also an autoimmune disease. The disease has a complex genetic background, great heterogeneity in clinical prognosis, and no specific treatment options. The "quadruple hit" pathogenesis hypothesis focuses on the key link in the occurrence of IgA nephropathy damage - complement activation, mainly the lectin pathway and the bypass pathway. In terms of participation in kidney progression, the former is more important.
[0005] As the main initiator of complement lectin pathway activation, MBL can recognize a variety of pathogenic microorganisms and plays an important role in natural immunity against a variety of pathogenic microorganisms. Studies have found that functional MBL deficiency may be the most common immune deficiency in humans, accounting for 10% of the population. It has been found that many diseases such as recurrent infections, primary and secondary immunodeficiency, cardiovascular disease and habitual abortion are associated with MBL deficiency, especially autoimmune diseases are closely related to abnormal MBL levels caused by MBL gene defects. Therefore, studying the role of MBL genetic variation in the progression of IgA nephropathy will help to intervene early and lay a theoretical foundation for targeted therapy of complement biological agents.
[0006] However, most of the existing mouse models are complete MBL gene knockouts. This mouse model in which all tissues and cells in the body do not express the gene is mostly used to study the physiological and pathological functions of the MBL coding gene on the whole body. For specific autoimmune diseases (such as IgA nephropathy), MBL complete gene knockout mice are not suitable as animal models for subsequent disease modeling. The CRISPR / Cas9 system can accurately edit specific gene sites in the genomes of mice and rats. Based on the applicant's previous findings in a large cohort study, the G54D point mutation of the MBL2 gene leads to a 37.1-fold increase in the risk of progression in patients with IgA nephropathy, but the mechanism of action is unclear. In addition, previous reports have never involved immune animal models of mice with MBL2-related point mutations. Summary of the invention
[0007] The present invention is based on the above research and uses CRISPR / Cas9 technology to knock out a specific gene mutation site in the mouse genome (corresponding to the G54D mutation of human MBL2), and establishes the G54D point mutation mouse of the MBL2 gene for the first time.
[0008] To achieve the above object, the present invention adopts the following technical solution:
[0009] The method for constructing the MBL point mutation animal model provided by the present invention is summarized as follows: after synthesizing gRNA and Donor Oligo, they are mixed to prepare an RNP complex; then the RNP complex is diluted and mixed with plasmid DNA to form an injection solution, which is injected into a fertilized egg and embryo transplantation is performed; the newly born F0 generation animals are identified, and the transgenic animals are passaged and established.
[0010] Preferably, the specific steps of the method for constructing the MBL point mutation animal model provided by the present invention are as follows:
[0011] 1. Synthesize gRNA and Donor Oligo
[0012] The nucleotide sequence of gRNA is as follows: GATGGGAGAGATGGACCCAAAGG (SEQ ID NO. 1);
[0013] The nucleotide sequence of Donor Oligo is as follows:
[0014] ACCTGTGAGGACACCCTGAAGACTTGCTCTGTGATAGCCTGTGGCAGAGATGGGAGAGAT GATC CCAAAGGGGAGAAGGGAGAACCAGGTATAGAGTACTGTACTCTGGCTTTACATCCAGTG (SEQ ID NO. 2).
[0015] 2. Preparation of RNP complex
[0016] (a) Solution in tube 1: add 15-16% M 100 pmol / μL crRNA to 15-16% M RNase-free water, then add 15-16% M 100 pmol / μL TracRNA, mix and incubate, then add 3-4% M Cas9 protein, mix and incubate to obtain solution in tube 1;
[0017] The crRNA (CRISPR RNA) sequence was purchased from IDT, and the tracrRNA (trans-activating crRNA) sequence was purchased from GenScript Biotech Co., Ltd. The crRNA will combine with the tracrRNA to form sgRNA.
[0018] (b) Solution in tube 2: Donor plasmid with a final concentration of 15 ng / μL;
[0019] (c) Mix the solution in tube 1 and the solution in tube 2 to obtain the RNP complex.
[0020] 3. Fertilized egg injection
[0021] The RNP complex and plasmid DNA were diluted and mixed to form an injection solution, in which the Cas9 protein concentration was 30 ng / μL; the concentrations of crRNA and TracRNA were both 2 pmol / μL; and the concentration of plasmid DNA was 15 ng / μL.
[0022] The injection solution is injected into the nucleus of the fertilized egg by microinjection. The fertilized egg after injection is transferred to M16 culture medium and placed in a constant temperature 37°C 5% CO2 incubator. After a certain period of incubation, it is transplanted.
[0023] 4. Identification, subculture and establishment of F0 generation animals
[0024] 4.1 Identification
[0025] The newly born F0 generation animals that have been identified as integrated are called founder animals. The identification method uses point mutation PCR detection and high-throughput sequencing PCR. The primer sequences of the two PCR detections are the same, as shown in Table 1 below:
[0026] Table 1 PCR primer sequences for point mutation detection and high-throughput sequencing
[0027] Primer sequences serial number F: 5'-AAGCTATAAGCCAAGTGAGATGGAATTTG-3' SEQ ID NO.3 R: 5'-CAAGCCTCTCCAGGTCATGGGTT-3' SEQ ID NO.4
[0028] When performing high-throughput sequencing, the forward primer sequence is used as a primer.
[0029] 4.2 Passaging and establishing lines:
[0030] (a) Mating and propagating animals carrying foreign genes with non-transgenic animals; each founder animal needs to be propagated independently;
[0031] (b) Identify the F1 generation animals born, and use the obtained F1 positive animals for experiments and further generation;
[0032] (c) If homozygotes are needed, the positive F1 from the same source may be mated with siblings. There is a 25% chance that the F2 animals born will be homozygous.
[0033] (d) Screen out mice that express the target gene, establish a stable lineage, and record the lineage status and pedigree.
[0034] The experimental animals that can be used in the present invention are non-human mammals; more preferably, the non-human mammals are rodents; most preferably, the rodents are mice. It is a mouse of the C57BL, C58, CBA / Br, CBA / Ca, CBA / J, CBA / st, CBA / H strains selected from BALB / c, A, A / He, A / J, A / WySN, AKR, AKR / A, AKR / J, AKR / N, TA1, TA2, RF, SWR, C3H, C57BR, SJL, C57L, DBA / 2, KM, NIH, ICR, CFW, FACA, C57BL / A, C57BL / An, C57BL / GrFa, C57BL / KaLwN, C57BL / 6, C57BL / 6J, C57BL / 6ByJ, C57BL / 6NJ, C57BL / 10, C57BL / 10ScSn, C57BL / 10Cr and C57BL / Ola.
[0035] In a second aspect, the present invention provides an MBL point mutation animal model, which is constructed using the construction method described above.
[0036] This animal model can be used for mechanism research of specific autoimmune diseases (such as IgA nephropathy), drug target screening, drug efficacy testing, library screening, efficacy evaluation, toxicology research, etc.
[0037] Compared with the prior art, the present invention has the following beneficial effects:
[0038] The present invention establishes for the first time a model animal with the G54D point mutation of the MBL2 gene. The model cannot normally express the G54D protein in vivo and can be used for functional studies of the G54D protein, such as the mechanism of IgA nephropathy caused by the G54D point mutation. The establishment and application of this animal model will help to deeply understand the role of the G54D point mutation in autoimmune diseases and its importance as a potential therapeutic target.
[0039] The animal model prepared by the present invention can be used for drug screening and efficacy research targeting G54D target sites, accelerate the new drug development process, save time and cost, and reduce drug development risks, providing a powerful tool for studying the function of G54D protein and drug screening. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 The sequence alignment of mouse and human G54D proteins is shown;
[0041] Figure 2 The results of the G54D protein sequence alignment between mouse and human are shown;
[0042] Figure 3 The results of PCR detection of the G54D point mutation are shown;
[0043] Figure 4 Results of sequencing homozygous mouse mutations are shown;
[0044] Figure 5 The results of heterozygous mouse mutation sequencing are shown;
[0045] Figure 6 The alignment of the same site in homozygous mice, heterozygous mice, and wild-type mice is shown;
[0046] Figure 7 The ELISA results of MBL levels in human (A) and mouse (B) peripheral blood are shown, ****, p < 0.0001;
[0047] Figure 8 The figure shows the changes in the proportion of Th2 (characteristic expression factor IL-4) and Th1 (characteristic expression factor IFN-γ) cells in CD3+CD4+ T cells detected in the spleen of mutant mice and wild-type mice;
[0048] Fig. 9 The statistical analysis of flow cytometry detection results of Th2 (A), Th1 (B), Th1 and Th2 (C) in CD3+CD4+ T cells detected in the spleen of mutant mice and wild-type mice (disease model group and non-disease model group) is shown. DETAILED DESCRIPTION
[0049] In order to make the purpose, technical solution and advantages of the embodiment of the present invention clearer, the technical solution of the embodiment of the present invention will be clearly and completely described below in conjunction with the accompanying drawings of the embodiment of the present invention. Obviously, the described embodiment is a part of the embodiment of the present invention, not all of the embodiments. Based on the described embodiment of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0050] 1. DNA alignment of protein sequences
[0051] Matrix:EBLOSUM62
[0052] Gap penalty: 2.0
[0053] Extend penalty: 2.0
[0054] Sequence 1length:249Human-MBL2-mRNA-NM_001378373.1
[0055] Sequence 2length:240Mouse-Mbl1-mRNA-NM_010775.2
[0056] Alignment length: 263
[0057] Identity: 154 / 263 (58.555%)
[0058] Similarity: 180 / 263 (68.441%)
[0059] Gaps: 37 / 263 (14.068%)
[0060] Score:758.0.
[0061] The comparison process of mouse and human G54D protein can be found in Figure 1 ,according to
[0062] "https: / / www.ncbi.nlm.nih.gov / snp / rs1800450#hgvs_tab" was used to analyze the results. For details, see Figure 2 .
[0063] 2. gRNA&DonorOligo synthesis
[0064] (a) Design gRNA for Mouse Mbl1 p.G43 site at http: / / crispor.tefor.net / and select high-scoring gRNA: gRNA1 (matches forward strand of gene):
[0065] GATGGGAGAGATGGACCCAAAGG (SEQ ID NO. 1);
[0066] (b) Artificially synthesized crRNA (CRISPR RNA) sequence (IDT) and tracrRNA (trans-activating crRNA) sequence (GenScript Biotech Co., Ltd.). crRNA will combine with tracrRNA to form sgRNA.
[0067] (c) Donor Oligo was synthesized at GenScript, the sequence is:
[0068] ACCTGTGAGGACACCCTGAAGACTTGCTCTGTGATAGCCTGTGGCAGAGATGGGAGAGAT GATC CCAAAGGGGAGAAGGGAGAACCAGGTATAGAGTACTGTACTCTGGCTTTACATCCAGTG (SEQ ID NO. 2).
[0069] 3. Preparation of RNP complex
[0070] (a) Solution in tube 1: add 0.8 μL of 100 pmol / μL crRNA to 5.2 μL RNase-free water, then add 0.6 μL of 100 pmol / μL TracRNA, mix well and incubate for 5 min, then add 0.2 μL Cas9 protein (NEB, catalog number: M0646M), mix well and incubate for 10 min to obtain solution in tube 1;
[0071] (b) Solution in tube 2: Donor plasmid with a final concentration of 15 ng / μL;
[0072] (c) Mix the solution in tube 1 and the solution in tube 2 to obtain the RNP injection complex.
[0073] 4. Preparation of fertilized eggs
[0074] (a) 3-4 week old C57BL / 6 female mice were selected and injected with pregnant mare serum (PMSG) and human chorionic gonadotropin (HCG) at an interval of 46-48 hours.
[0075] (b) After HCG injection, the female mouse is mated with an adult fertile male mouse to fertilize the female mouse;
[0076] (c) The next day, the female mouse was euthanized, and the fertilized eggs were collected from the oviduct and placed in a 37°C 5% CO2 incubator for later use;
[0077] 5. Pronuclear microinjection
[0078] (a) Preparation of microinjection needles and fixation needles;
[0079] (b) The prepared RNP complex and plasmid DNA are diluted and mixed to form an injection solution, and then the injection solution is added to the microinjection needle. The concentration of Cas9 protein in the injection solution is 30 ng / μL; the concentration of crRNA and TracRNA is 2 pmol / μL; the concentration of plasmid DNA is 15 ng / μL;
[0080] (c) selecting fertilized eggs with normal morphology and placing them in an injection dish, and injecting the exogenous gene injection solution into the nucleus of the fertilized egg by microinjection under an inverted microscope at a magnification of 200-400 times;
[0081] (d) The injected fertilized eggs were transferred into M16 culture medium and placed in a 37°C 5% CO2 incubator for 0.5-1 hour before transplantation; the transplantation was performed the next day.
[0082] 6. Preparation of surrogate mice and embryo transplantation
[0083] (a) Preparing pseudo-pregnant female mice: Select fertile female mice of appropriate age and mate them with male mice that have been sterilized after vasectomy to stimulate a series of pregnancy changes in the female mice to obtain pseudo-pregnant female mice, which will serve as surrogate mice for the transgenic fertilized eggs;
[0084] (b) Transplanting the fertilized egg injected with the foreign gene into the oviduct of the surrogate mother mouse on the day of follicle rupture;
[0085] (c) After transplantation, place the surrogate mother mouse in a clean cage and keep it warm until it wakes up and then return it to the cage for feeding;
[0086] (d) After successful fallopian tube transplantation, the mother mouse will generally give birth 19-20 days after the operation;
[0087] One week after birth, the mice can have their claws clipped and numbered, and PCR identification performed at the same time; three weeks after birth, the mice can be raised independently in separate cages.
[0088] 7. Identification of F0 mice
[0089] (a) Collect tissues (tail or toe tissues) from 1-2 week old mice;
[0090] (b) lysing the tissue and extracting the genome;
[0091] (c) using specific primers for the target gene to perform PCR amplification and electrophoresis detection to screen out offspring with the integration of the exogenous gene;
[0092] (d) Mice with integration are called founder mice, which can be passaged and established, and protein expression levels can be identified if necessary.
[0093] 7.1Region 1 PCR
[0094] (1) Primers:
[0095] F1:5'-AAGCTATAAGCCAAGTGAGATGGAATTTG-3' (SEQ ID NO.3),
[0096] R1: 5'-CAAGCCTCTCCAGGTCATGGGTT-3' (SEQ ID NO. 4).
[0097] (2) Expected PCR product
[0098] Wild type: 305bp
[0099] Targeted:305bp
[0100] (3) Reaction system
[0101] See Table 2 and Table 3 below:
[0102] Table 2 PCR reaction system
[0103] Components Volume (μL) Mouse genomic DNA 1.5 Forward primer (10 μM) 1.0 Reverse primer (10 μM) 1.0 Taq polymerase 12.5 <![CDATA[ddH2O]]> 9.0 Total 25.0
[0104] Table 3 Reaction conditions
[0105]
[0106]
[0107] The identification results can be found in Figure 3, the G54D point mutation mice of MBL2 gene were successfully constructed. Among them, 1#, 2#, 3#, 4#, 5#, 7#, 8#, 9#, 10#, 11#, 20#, 26#, 27# and 28# are positive target mice.
[0108] 8. Passaging and establishment of transgenic mice
[0109] (a) Mating and passage of mice carrying foreign genes with non-transgenic mice; each founder mouse needs to be passaged independently;
[0110] (b) Identify the born F1 mice, and use the obtained F1 positive mice for experiments and further generation;
[0111] (c) If homozygous mice are needed, the positive F1 mice from the same source may be crossbred, and the F2 mice born will have a 25% chance of being homozygous.
[0112] (d) Screening out mice that express the target gene, establishing a stable lineage, and recording the passage status and lineage;
[0113] High-throughput sequencing was used to sequence mutations in homozygous and heterozygous mice, as follows:
[0114] (1) High-throughput PCR primers:
[0115] Seq-F(F1):5'-AAGCTATAAGCCAAGTGAGATGGAATTTG-3'(SEQ ID NO.3),
[0116] Seq-R(R1): 5'-CAAGCCTCTCCAGGTCATGGGTT-3' (SEQ ID NO. 4).
[0117] (2) Expected PCR product:
[0118] Wild type: 305bp
[0119] Product Size:305bp
[0120] (3) Sequencing primers:
[0121] Seq-F(F1): 5'-AAGCTATAAGCCAAGTGAGATGGAATTTG-3' (SEQ ID NO. 3).
[0122] Mbl1-1#(Seq-F): Homozygous mutation sequencing results see Figure 4 ,Mbl1-3#(Seq-F): heterozygous mutation sequencing results see Figure 5 For the alignment of the same site in homozygous mice, heterozygous mice, and wild-type mice, see Figure 6 .
[0123] Through high-throughput sequencing, 1#, 2#, 3#, 4#, 5#, 7#, 8#, 9#, 10#, 11#, 20#, 26#, 27# and 28# were identified as G54D point mutation mice.
[0124] 9. Phenotypic identification of transgenic mice
[0125] 9.1 Detection of MBL levels in mice of different genotypes
[0126] Peripheral blood was collected from homozygous mice, heterozygous mice, and wild-type mice, and ELISA was used to detect whether the MBL level in peripheral blood was low. The results are shown in Figure 7 .
[0127] The Mann-Whitney U results showed that mice ( Figure 7 B) with people ( Figure 7 A) showed the same trend of different mutation types, with the wild type being the highest, followed by the heterozygote, and the homozygote being the lowest. Among them, 13 homozygous mice had an MBL level of 34.34 ng / ml; 14 heterozygous mice had an MBL level of 3203 ng / ml; and 11 wild-type mice had an MBL level of 5457 ng / ml. Therefore, the MBL level of heterozygous mice decreased, while the MBL level of homozygous mice was only 34.34 ng / ml (lower than the PBS blank control level of 37.66 ng / ml), indicating that the G54D point mutation mouse model of MBL deficiency was successfully established.
[0128] 9.2 Flow cytometry detection of T cell subsets
[0129] The spleens of mutant mice (disease model group) and wild-type mice (normal type) were tested for changes in the proportion of Th2 (characteristic expression factor IL-4) and Th1 (characteristic expression factor IFN-γ) cells in CD3+CD4+T cells, and the flow cytometry results were statistically analyzed. Figure 8 and Fig. 9 The results showed that the proportions of Th2 and Th1 cells in the cell subsets of mutant mice and wild-type mice were significantly different.
[0130] The preferred embodiments of the present invention have been specifically described above, but the present invention is not limited to the embodiments. Those skilled in the art may make various equivalent modifications or substitutions without violating the spirit of the present invention. These equivalent modifications or substitutions are all included in the scope defined by the claims of this application.
Claims
1. A method for constructing an MBL point mutation animal model, characterized in that: After synthesizing gRNA and Donor Oligo, they are mixed to prepare RNP complex; then the RNP complex is diluted and mixed with plasmid DNA to form an injection solution, which is injected into fertilized eggs and embryo transplantation is performed; the newly born F0 generation animals are identified, and the transgenic animals are passaged and established.
2. The method for constructing an MBL point mutation animal model according to claim 1, characterized in that: in, The nucleotide sequence of gRNA is shown in SEQ ID NO.1, and the nucleotide sequence of Donor Oligo is shown in SEQ ID NO.
2.
3. The method for constructing an MBL point mutation animal model according to claim 1, Features: Wherein, the method for preparing the RNP complex is as follows: (a) Solution in tube 1: add 15-16% M 100 pmol / μL crRNA to 15-16% M RNase-free water, then add 15-16% M 100 pmol / μL TracRNA, mix and incubate, then add 3-4% M Cas9 protein, mix and incubate to obtain solution in tube 1; (b) Solution in tube 2: Donor plasmid with a final concentration of 15 ng / μL; (c) Mix the solution in tube 1 and the solution in tube 2 to obtain the RNP complex.
4. The method for constructing an MBL point mutation animal model according to claim 1, characterized in that: in, The concentration of Cas9 protein in the injection solution is 30 ng / μL; the concentrations of crRNA and TracRNA are both 2 pmol / μL; the concentration of plasmid DNA is 15 ng / μL, The injection solution is injected into the nucleus of the fertilized egg by microinjection. The fertilized egg after injection is transferred to M16 culture medium and placed in a constant temperature 37°C 5% CO2 incubator. After a certain period of incubation, it is transplanted.
5. The method for constructing an MBL point mutation animal model according to claim 1, characterized in that: in, The newly born F0 generation animals that have been identified as integrated are called founder animals, and they are passaged and line-established: (a) Mating and propagating animals carrying foreign genes with non-transgenic animals; each founder animal needs to be propagated independently; (b) Identify the F1 generation animals born, and use the obtained F1 positive animals for experiments and further generation; (c) If homozygotes are needed, the positive F1 from the same source may be mated with siblings. There is a 25% chance that the F2 animals born will be homozygous. (d) Screen out mice that express the target gene, establish a stable lineage, and record the lineage status and pedigree.
6. The method for constructing an MBL point mutation animal model according to claim 1, characterized in that: in, The experimental animals were non-human mammals.
7. The method for constructing an MBL point mutation animal model according to claim 1, characterized in that: in, The experimental animals were rodents.
8. The method for constructing an MBL point mutation animal model according to claim 1, characterized in that: in, The point mutation is the G54D point mutation of the MBL2 gene.
9. The method for constructing an MBL point mutation animal model according to claim 8, characterized in that: in, The PCR primer sequences for point mutation detection and the primer sequences for high-throughput sequencing PCR detection are shown in SEQ ID NOs. 3 and 4, respectively.
10. An MBL point mutation animal model, characterized in that: The method is constructed by any one of claims 1 to 5.
